TME Pharma AG

General information
TME Pharma AG
Max-Dohrn-Strasse 8-10
10589 Berlin, Berlin
Germany

Contact person: Aram Mangasarian, Chief Executive Officer
Company main phone: +49 (30) 16637082 0
Website:  https://www.tmepharma.com
Year founded:1997
Source of foundation:Independent foundation
Corporate description / mission:
TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. The company specializes in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. The technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact.
State of ownership: Publicly listed on stock exchange
Headquarters: HQ: Yes
IPO (year): 2016
Remarks on ownership / listings
Formerly called NOXXON Pharma AG.
Categorization
Sector:
  • Biotechnology - Therapeutics and Diagnostics
Subsector:
  • Immunotherapy
Primary therapeutic areas:
  • Neoplasms / cancer / oncology
Business model:
  • R&D
Customer segments:
  • Large biotech & big pharma
  • Small biotech
Distribution:
  • Indirect (independent dealer)
Summary Products / Services / Technologies
Number of Biotech Products
Phase II:3
Description of products:
NOX-A12
NOX-E36
Technology used:
Spiegelmer
Financing details
Market cap. / valuation:EUR 3.05M
Collaborations & Clients
Partnering strategy / collaborations:
Merck & Co. / MSD
© 2024 Biotechgate by Venture Valuation
X